D.A. Davidson & Co. Amgen Inc Transaction History

D.A. Davidson & Co.

$12 Billion
Q3 2024

A detailed history of D.A. Davidson & Co. transactions in Amgen Inc stock. As of the latest transaction made, D.A. Davidson & Co. holds 217,734 shares of AMGN stock, worth $63.1 Million. This represents 0.59% of its overall portfolio holdings.

Number of Shares

217,734

Previous 212,678 2.38%

Holding current value

$63.1 Million

Previous $66.5 Million 5.58%

% of portfolio

0.59%

Previous 0.59%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$309.38 - $337.38 $1.56 Million - $1.71 Million	5,056 Added 2.38%	217,734 $70.2 Million
Q2 2024 Jul 31, 2024	SELL	$262.75 - $319.31 $464,542 - $564,540	-1,768 Reduced 0.82%	212,678 $66.5 Million
Q1 2024 May 13, 2024	BUY	$268.87 - $324.56 $1 Million - $1.21 Million	3,725 Added 1.77%	214,446 $61 Million
Q4 2023 Feb 09, 2024	BUY	$255.7 - $288.46 $319,113 - $359,998	1,248 Added 0.6%	210,721 $60.7 Million
Q3 2023 Nov 08, 2023	BUY	$218.65 - $271.46 $874,162 - $1.09 Million	3,998 Added 1.95%	209,473 $56.3 Million
Q2 2023 Aug 10, 2023	BUY	$214.27 - $253.37 $628,668 - $743,387	2,934 Added 1.45%	205,475 $45.6 Million
Q1 2023 Apr 25, 2023	BUY	$225.79 - $275.2 $1.87 Million - $2.28 Million	8,282 Added 4.26%	202,541 $49 Million
Q4 2022 Feb 03, 2023	SELL	$229.03 - $291.01 $709,763 - $901,839	-3,099 Reduced 1.57%	194,259 $51 Million
Q3 2022 Nov 07, 2022	SELL	$224.46 - $253.15 $801,771 - $904,251	-3,572 Reduced 1.78%	197,358 $44.5 Million
Q2 2022 Jul 28, 2022	BUY	$230.71 - $256.74 $377,902 - $420,540	1,638 Added 0.82%	200,930 $48.9 Million
Q1 2022 May 12, 2022	BUY	$219.27 - $242.57 $4.86 Million - $5.38 Million	22,159 Added 12.51%	199,292 $48.2 Million
Q4 2021 Jan 31, 2022	SELL	$198.88 - $227.6 $944,878 - $1.08 Million	-4,751 Reduced 2.61%	177,133 $39.9 Million
Q3 2021 Nov 15, 2021	BUY	$212.27 - $248.7 $786,672 - $921,682	3,706 Added 2.08%	181,884 $38.7 Million
Q2 2021 Aug 10, 2021	BUY	$233.58 - $259.14 $2.98 Million - $3.3 Million	12,737 Added 7.7%	178,178 $43.4 Million
Q1 2021 May 07, 2021	BUY	$221.91 - $258.6 $11.1 Million - $12.9 Million	50,071 Added 43.4%	165,441 $41.2 Million
Q4 2020 Feb 10, 2021	BUY	$216.38 - $257.67 $1.02 Million - $1.22 Million	4,719 Added 4.26%	115,370 $26.5 Million
Q3 2020 Nov 02, 2020	BUY	$234.65 - $260.95 $720,610 - $801,377	3,071 Added 2.85%	110,651 $28.1 Million
Q2 2020 Aug 10, 2020	SELL	$197.81 - $242.74 $7.29 Million - $8.94 Million	-36,840 Reduced 25.51%	107,580 $25.4 Million
Q1 2020 May 05, 2020	BUY	$182.24 - $241.7 $2.75 Million - $3.65 Million	15,105 Added 11.68%	144,420 $29.3 Million
Q4 2019 Feb 14, 2020	BUY	$189.21 - $243.2 $526,760 - $677,068	2,784 Added 2.2%	129,315 $31.2 Million
Q3 2019 Nov 05, 2019	BUY	$174.11 - $208.62 $1.86 Million - $2.22 Million	10,660 Added 9.2%	126,531 $24.5 Million
Q2 2019 Aug 13, 2019	SELL	$166.7 - $195.41 $1.1 Million - $1.3 Million	-6,628 Reduced 5.41%	115,871 $21.4 Million
Q1 2019 May 13, 2019	BUY	$180.87 - $203.88 $2.72 Million - $3.07 Million	15,047 Added 14.0%	122,499 $23.3 Million
Q4 2018 Jan 29, 2019	BUY	$178.4 - $208.25 $1.48 Million - $1.73 Million	8,314 Added 8.39%	107,452 $20.9 Million
Q3 2018 Nov 13, 2018	BUY	$185.29 - $208.89 $323,516 - $364,721	1,746 Added 1.79%	99,138 $20.6 Million
Q2 2018 Aug 02, 2018	BUY	$166.05 - $186.51 $1.34 Million - $1.51 Million	8,081 Added 9.05%	97,392 $18 Million
Q1 2018 May 04, 2018	BUY	$169.43 - $198.0 $943,894 - $1.1 Million	5,571 Added 6.65%	89,311 $15.2 Million
Q4 2017 Feb 08, 2018	BUY	$168.79 - $188.59 $1.23 Million - $1.38 Million	7,293 Added 9.54%	83,740 $14.6 Million
Q3 2017 Nov 08, 2017	BUY	$167.29 - $191.0 $48,514 - $55,390	290 Added 0.38%	76,447 $14.3 Million
Q2 2017 Aug 11, 2017	BUY	N/A	76,157	76,157 $0

Others Institutions Holding AMGN

# of Institutions

3,122

Shares Held

410M

Call Options Held

7.56M

Put Options Held

7.2M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $155B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D.A. Davidson & Co., based on Form 13F filings with the SEC.

News

Stay updated on D.A. Davidson & Co. with notifications on news.

Account